Exelixis
EXEL
#1820
Rank
A$16.53 B
Marketcap
A$61.43
Share price
-1.23%
Change (1 day)
11.66%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): A$3.63

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$3.58. In 2023 the company made an earnings per share (EPS) of A$0.98 an increase over its 2022 EPS that were of A$0.86.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$3.63
2023A$0.9814.61%
2022A$0.86-22.97%
2021A$1.11100%
2020A$0.56-65.09%
2019A$1.59-53.91%
2018A$3.46333.96%
2017A$0.80-260.61%
2016A-$0.50-58.75%
2015A-$1.20-42.45%
2014A-$2.095.3%
2013A-$1.98

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
A$5.40 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
A$5.57 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$11.41 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$4.46 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$19.58 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
A$15.69 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$2.58-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
A-$5.51-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.26-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA